Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Needham Downgrades Varonis Systems to Hold

Needham Downgrades Varonis Systems to Hold

Needham analyst Alex Henderson downgrades Varonis Systems (NASDAQ:VRNS) from Buy to Hold.

byBenzinga Newsdesk

February 2, 2023

1 minute read

Needham analyst Alex Henderson downgrades Varonis Systems (NASDAQ:VRNS) from Buy to Hold.

Susquehanna Reiterates Positive on Nutanix, Maintains $34 Price Target

By Benzinga Newsdesk

March 9, 11:53 AM

Susquehanna analyst Mehdi Hosseini reiterates Nutanix (NASDAQ:NTNX) with a Positive and maintains $34 price target.

NTNX

News

Jana Partners Has Nearly 10% Stake In FreshPet; Jana Partners Plans To Push FreshPet To Make Changes To Boost Stock Price, Explore Sale – Wall Street Journal

By Benzinga Newsdesk

September 22, 3:34 PM

- Reuters Citing WSJ

FRPT

GOP Governor Greg Abbott Welcomes Elon Musk With Open Arms As Tesla Shareholders Approve Corporation Move To Texas: ‘It Was Meant To Be’

By Ananya Gairola

June 14, 11:19 PM

Texas Governor Greg Abbott welcomed Tesla's move to Texas, a decision solidified by shareholder approval and celebrated by CEO Elon Musk.

TSLA

InspireMD Announces Abstract Of 30-Day Results From The C-Guardians U.S. Investigational Device Exemption Clinical Trial Accepted for Presentation at VIVA23

By Happy Mohamed

August 31, 8:07 AM

InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract detailing upcoming 30-day results from its C-Guardians

NSPR

Needham Downgrades Varonis Systems to Hold

Related Posts

Susquehanna Reiterates Positive on Nutanix, Maintains $34 Price Target

Jana Partners Has Nearly 10% Stake In FreshPet; Jana Partners Plans To Push FreshPet To Make Changes To Boost Stock Price, Explore Sale – Wall Street Journal

GOP Governor Greg Abbott Welcomes Elon Musk With Open Arms As Tesla Shareholders Approve Corporation Move To Texas: ‘It Was Meant To Be’

InspireMD Announces Abstract Of 30-Day Results From The C-Guardians U.S. Investigational Device Exemption Clinical Trial Accepted for Presentation at VIVA23